查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095371

新冠疫苗市場－2026-2032年全球市場預測

COVID-19 Vaccines Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，新冠肺炎疫苗市場規模將達到 114 億美元，複合年成長率為 6.46%。

主要市場統計數據
基準年 2025 73.5億美元
預計年份：2026年 78.4億美元
預測年份 2032 114億美元
複合年成長率 (%) 6.46%

隨著SARS-CoV-2病毒從急性大流行威脅演變為一種週期性變異的流行性呼吸道病原體，新冠疫苗仍然是全球公共衛生策略的關鍵支柱。目前疫苗研發的特點包括：持續為高風險族群接種疫苗、研發可應對變異株的疫苗配方、改善加強免疫策略、最佳化低溫運輸運輸以及更廣泛地與呼吸道疾病防治工作相結合。監管機構和公共衛生部門正在從緊急的大規模疫苗宣傳活動轉向基於風險的季節性疫苗接種計劃，尤其關注老年人、免疫力缺乏者、醫護人員、孕婦以及患有基礎疾病的人。此外，疫苗的可靠性、公平取得、安全監測、生產能力以及快速應對新出現的變異株的能力等問題也持續存在，並影響疫苗研發工作。與 SEO 相關的議題，例如 mRNA 疫苗、蛋白質疫苗、病毒載體疫苗、加強針、疫苗安全性、變異反應疫苗、COVID-19 免疫計劃、真實世界療效、基因組監測和疫情應對，繼續決定著各國政府、醫療保健提供者、保險公司和生命科學組織等相關人員的優先事項。

新冠疫苗領域發生的變革性變化

自新冠疫苗最初緊急部署以來，其發展格局已發生巨大變化。早期重點在於快速研發、緊急使用授權、大規模採購以及為大規模接種建立基礎設施。而目前的重點則轉向持續預防重症、有針對性的加強劑量建議、更新的抗原成分、上市後安全性監測以及改善對外溝通。傳訊RNA（mRNA）平台加速了高適應性疫苗技術的應用。同時，基於蛋白質、去活化和病毒載體的疫苗方法也促進了疫苗組合和獲取策略的多樣化。各國免疫規劃正日益將新冠疫苗接種與流感和呼吸道融合細胞病毒（RSV）預防宣傳活動相結合，從而提高了運作效率並擴大了患者覆蓋範圍。另一個顯著的變化是，疫苗採購模式從疫情期間的集中採購轉變為透過診所、藥局、醫院、基層醫療機構和社區健康計畫等常規醫療服務管道進行。同時，世界各國政府正持續加強國內生產能力、區域灌裝和包裝能力、基因組監測、藥物安全監測系統以及儲備計畫。這些結構性變化正在重塑全球疫苗的採購、分發、臨床試驗設計、監管審查和公共衛生決策。

人工智慧對新冠疫苗的累積影響

人工智慧 (AI) 對新冠疫苗的研發、生產、分發和安全監測的影響日益顯著。 AI 驅動的蛋白質建模和免疫資訊學透過分析病毒突變、免疫逃脫模式以及不同變異株之間的表位保守性，輔助抗原選擇。機器學習工具正被用於改進臨床試驗設計，包括候選疫苗篩檢、製劑最佳化、臨床實驗選擇、受試者分層、方案可行性評估以及真實世界數據 (REW) 的整合。在生產製造方面，AI 和先進的分析技術有助於監控制程一致性、預測設備維護需求、降低批間差異並加強品管。在供應鏈方面，預測模型能夠改善需求規劃、低溫運輸規劃、庫存分配和減少浪費。當疫苗接種率因季節、風險族群和公共政策而異時，這一點尤其重要。此外，AI 還透過檢測來自不利事件通報系統、電子健康記錄、保險理賠數據和已發表文獻的安全訊號，加強藥物警戒。然而，在 COVID-19 疫苗中使用人工智慧需要透明的管治、經過驗證的資料集、網路安全措施、偏見緩解、人工監督和明確的監管，以檢驗數據驅動的決策在科學上是可靠的，在倫理上課責的。

亞太地區、歐洲、北美、拉丁美洲、非洲和中東的關鍵區域洞察

亞太地區在新冠疫苗的生產、部署和監測方面繼續發揮核心作用，中國、印度、日本、韓國和澳洲在疫苗生產、臨床研究、法律規範和免疫接種實施方面各自扮演著獨特的角色。該地區龐大的人口基數、人口密集的都市區以及多元化的醫療衛生基礎設施，凸顯了可擴展的免疫接種體系、國內生產能力、數位證書以及應對新出現的變異株的準備工作的重要性。在歐洲，各國強調在國家衛生系統之間進行協調一致的監管評估、制定聯合科學指導方針、提高疫苗安全性透明度以及與季節性免疫接種相結合，同時繼續關注老年人、免疫力缺乏者和醫護人員的需求。北美在成熟的監管體系和整合的醫療衛生數據的支持下，正朝著基於風險的加強免疫接種指導、藥屋主導的疫苗獲取、先進的安全監測、疫苗配方更新和強力的基因組監測方向發展。拉丁美洲則持續致力於提高弱勢族群的加強免疫接種率，加強與基層醫療的整合，並解決都市區、農村、偏遠地區和原住民社區在疫苗取得方面的差距。非洲新冠疫苗的格局受到公平取得、最後一公里配送、低溫運輸限制、疫苗信任度以及在更廣泛的衛生安全議程下擴大區域生產計劃等因素的影響。在中東，儘管數位化疫苗接種記錄、邊境檢疫系統和醫療衛生現代化舉措正在推進，但保護高風險族群、居住者和慢性病患者仍然是重中之重。在所有地區，政策重點都在轉向永續的免疫基礎設施、變異株監測、透明的安全資訊傳播以及應對未來冠狀病毒威脅的準備工作。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會的關鍵群體特定見解

北約成員國致力於在衛生安全、軍事戰備、勞動力連續性、關鍵基礎設施韌性以及保護部署人員和基本服務等方面推進新冠疫苗接種。七國集團（G7）在引領疫苗研發、制定監管標準、提供疫情應對資金、開展基因組監測以及支持旨在實現公平獲取和做好感染疾病疫情應對準備的全球衛生舉措仍然發揮著重要作用。金磚國家在疫苗生產、技術轉移、臨床研究和南南衛生合作方面發揮關鍵作用，成員國致力於加強新興經濟體的國內免疫規劃和供應韌性。歐盟在協調監管審查、藥品安全監測、採購協調、安全資訊傳播和公共衛生指導方面發揮了重要作用，成員國仍負責其國內免疫規劃和實施模式。東南亞國協繼續優先考慮區域衛生合作、跨境監測以及在其高度多樣化的醫療衛生系統中切實有效地實施免疫接種，新冠疫苗接種計劃正日益融入成人常規免疫接種和公共衛生應急準備工作中。海灣合作理事會（GCC）充分利用其集中化的醫療衛生管治、數位健康平台和強大的物流能力，支持疫苗的取得、認證、加強免疫接種以及對高流動性族群的保護。這些機構共同對疫苗外交、監管協調、生產在地化、籌資策略、建立公眾信任以及整個全球新冠疫苗生態系統的準備規劃產生了重大影響。

對各國主要新冠疫苗市場的關鍵洞察。

中國正著力推動國內大規模疫苗接種，提高老年族群的接種率，並持續評估疫苗對變異株的保護效果，這得益於國內疫苗研發和廣泛的公共衛生體系的調動。美國正將新冠疫苗接種納入常規醫療流程，並制定更新的疫苗接種建議，重點在於預防老年人、免疫力缺乏低下者和其他高風險族群重症。日本優先考慮安全資訊傳播、保護老年人以及透過地方政府系統有序開展加強免疫接種；印度則將大規模疫苗生產能力與廣泛的公共衛生服務網路和數位證書基礎設施相結合。德國、英國、法國、義大利和西班牙繼續根據科學顧問委員會的建議、適用的歐洲監管指南、老年人保護、季節性呼吸道疾病預防宣傳活動以及醫療體系容量規劃調整其疫苗接種政策。澳洲正在實施基於風險的接種建議，並以基層醫療和藥房疫苗接種系統為支援；韓國正在製定一項結合數位醫療系統、強力的公共衛生協調和變異株監測的疫苗接種策略。加拿大正專注於公共衛生指南、省和地區免疫接種系統、原住民和偏遠社區的疫苗接種途徑以及持續的安全監測。俄羅斯則在維護國內疫苗研發能力和公共部門免疫接種系統。巴西正利用其已建立的國家免疫接種基礎設施來支持廣泛的免疫接種和加強宣傳活動，而墨西哥則致力於確保透過公共免疫接種途徑獲得疫苗，並保護弱勢群體。這些國家的通用優先事項包括：改善疫苗取得途徑、建立公眾信心、監測不利事件、確保公平免疫接種，以及將新冠疫苗接種納入長期呼吸系統疾病管理。

為新冠疫苗產業領導者提供的實用建議

產業領導者應優先開發靈活的疫苗平台、應對變異株的製劑策略，並著重研究疫苗預防重症、住院和具有重要醫學意義的後果的有效性。各組織應投資於真實世界數據、免疫橋接研究、藥物安全監測分析以及透明的安全資訊傳播，以增強監管機構和公眾的信心。生產策略應強調靈活的生產能力、供應商多元化、品質源於設計 (QbD) 系統、經過驗證的檢驗流程以及穩健的低溫運輸物流，以降低中斷風險。商業和公共衛生團隊應使疫苗獲取模式與成人常規免疫接種途徑、藥房、基層醫療網路、職業健康計劃、長期護理機構和社區參與相協調。領導者還應加強與政府、學術機構、公共衛生機構和多邊組織的合作，以改善監測、數據共用和公平分配。包括人工智慧驅動的需求預測和安全監測在內的數位化工具，應在嚴格的檢驗、隱私保護、網路安全措施和管治下實施。為了提高疫苗接種率，傳播策略必須透過值得信賴的醫療保健專業人員和社區傳播者來解決疫苗接種疲勞、錯誤訊息、風險認知和特定文化方面的擔憂。

新冠病毒疫苗資訊的調查方法

本執行摘要採用系統性的二手研究途徑，基於檢驗的公共衛生、監管、科學和政策資訊來源編寫而成。調查方法包括審查國家和國際衛生機構的指南、疫苗諮詢委員會的建議、監管更新、同行評審的科學文獻、免疫規劃文件、藥物安全監測出版物以及公開的流行病學監測數據。評估證據的依據包括資訊來源的可靠性和時效性、調查方法的透明度及其與新冠疫苗的研發、核准、部署、安全監測、取得和公共衛生影響的相關性。透過對疫苗接種政策、醫療基礎設施、生產能力、取得條件、監測系統和準備工作的優先事項進行比較分析，整合了區域、群體和國家層面的具體見解。本研究避免做出不實預測，不涉及市場規模、市場佔有率或預測。相反，它側重於數據支援的定性資訊、可觀察的政策轉變、技術部署、監管趨勢以及影響新冠疫苗格局的營運因素。

關於新冠疫​​苗作用變化的結論

新冠疫苗已從緊急應變措施轉變為呼吸道疾病預防、衛生安全和免疫政策的常態化組成部分。如今，這一領域的特點是：適應病毒變異、制定有針對性的加強免疫策略、提供真實世界療效證據、確保安全性透明、提升生產韌性以及實現公平獲取。醫療基礎設施、公眾信任度、監管協調和供給能力的區域和國家差異，持續影響疫苗接種率和專案設計。人工智慧、基因組監測和先進的分析技術正在增強檢測病毒變異、最佳化疫苗研發、管理供應鏈和監測安全訊號的能力。對於產業領導者而言，成功的關鍵在於科學的敏捷性、與公共衛生部門的合作、可信賴的溝通、穩健的營運以及在整個疫苗生態系統中持續的合作。隨著SARS-CoV-2病毒的持續傳播，新冠疫苗接種仍將是確保應對未來變異病毒、長期管理呼吸道疾病以及增強應對更廣泛疫情能力的核心要素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：新冠疫苗市場：依疫苗技術分類

  • 失活
  • mRNA
  • 蛋白質次單元
    • 含佐劑型
    • 非輔助型

第8章：新冠疫苗市場：依劑量方法分類

  • 加強劑量
  • 1. 接種疫苗
  • 兩劑疫苗

第9章：新冠疫苗市場：依包裝類型分類

  • 預填充式注射器
  • 管瓶

第10章：新冠疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 鼻內給藥

第11章：新冠肺炎疫苗市場：依最終用戶分類

  • 青年
  • 成人
  • 兒童

第12章：新冠疫苗市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：新冠疫苗市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：新冠肺炎疫苗市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AIVITA Biomedical, Inc.
  • Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Baseimmune Ltd.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • CanSino Biologics Inc.
  • Centivax, Inc.
  • Codagenix Inc.
  • CureVac SE
  • Emergex Vaccines Holding Ltd.
  • eTheRNA immunotherapies NV
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline plc
  • HDT Bio Corp.
  • Johnson & Johnson
  • Medicago Inc.
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Osivax SAS
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Providence Therapeutics Holdings Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • Vaccitech PLC
  • Valneva SE
  • VBI Vaccines Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market is projected to grow by USD 11.40 billion at a CAGR of 6.46% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.35 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 11.40 billion
CAGR (%) 6.46%

COVID-19 vaccines remain a critical pillar of global public health strategy as SARS-CoV-2 continues to evolve from an acute pandemic threat into an endemic respiratory pathogen with periodic variant-driven waves. The vaccine landscape is defined by continued immunization of high-risk populations, variant-adapted formulations, booster policy refinement, cold-chain optimization, and broader integration with respiratory disease preparedness. Regulatory agencies and public health authorities have moved from emergency mass vaccination campaigns toward risk-based, seasonally aligned vaccination programs, particularly for older adults, immunocompromised individuals, healthcare workers, pregnant people, and people with underlying medical conditions. The sector is also shaped by persistent concerns around vaccine confidence, equitable access, safety monitoring, manufacturing resilience, and rapid response capacity for new variants. SEO-relevant themes including mRNA vaccines, protein-based vaccines, viral vector vaccines, booster doses, vaccine safety, variant-adapted vaccines, COVID-19 immunization programs, real-world effectiveness, genomic surveillance, and pandemic preparedness continue to frame stakeholder priorities across governments, healthcare providers, payers, and life sciences organizations.

Transformative Shifts in the COVID-19 Vaccine Landscape

The COVID-19 vaccine landscape has transformed significantly since the initial emergency rollout. Early priorities centered on rapid development, emergency authorization, large-scale procurement, and mass vaccination infrastructure. Current priorities emphasize durable protection against severe disease, targeted booster recommendations, updated antigen composition, post-authorization safety surveillance, and improved public communication. Messenger RNA platforms accelerated the use of adaptable vaccine technologies, while protein-based, inactivated, and viral vector approaches contributed to portfolio diversity and access strategies. National immunization programs increasingly align COVID-19 vaccination with influenza and respiratory syncytial virus prevention campaigns, improving operational efficiency and patient outreach. Another major shift is the movement from centralized pandemic purchasing toward routine healthcare delivery through clinics, pharmacies, hospitals, primary care practices, and community health programs. At the same time, governments continue to strengthen domestic manufacturing, regional fill-finish capabilities, genomic surveillance, pharmacovigilance systems, and stockpile planning. These structural changes are reshaping vaccine procurement, distribution, clinical trial design, regulatory review, and public health decision-making worldwide.

Cumulative Impact of Artificial Intelligence on COVID-19 Vaccines

Artificial intelligence is increasingly influencing COVID-19 vaccine research, development, manufacturing, distribution, and safety monitoring. AI-enabled protein modeling and immunoinformatics support antigen selection by analyzing viral mutations, immune escape patterns, and epitope conservation across variants. Machine learning tools are used to screen vaccine candidates, optimize formulations, and improve clinical trial design through site selection, patient stratification, protocol feasibility assessment, and real-world evidence integration. In manufacturing, AI and advanced analytics help monitor process consistency, predict equipment maintenance needs, reduce batch variability, and strengthen quality control. In supply chains, predictive models improve demand planning, cold-chain routing, inventory allocation, and wastage reduction, particularly when vaccination uptake varies by season, risk group, and public policy. AI also enhances pharmacovigilance by detecting safety signals across adverse event reporting systems, electronic health records, claims data, and published literature. However, the use of artificial intelligence in COVID-19 vaccines requires transparent governance, validated datasets, cybersecurity safeguards, bias mitigation, human oversight, and regulatory clarity to ensure that data-driven decisions remain scientifically robust and ethically accountable.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East

Asia-Pacific remains central to COVID-19 vaccine production, public health deployment, and variant surveillance, with China, India, Japan, South Korea, and Australia playing distinct roles across manufacturing, clinical research, regulatory oversight, and immunization delivery. Large populations, dense urban centers, and diverse healthcare infrastructure have driven strong emphasis on scalable vaccination systems, domestic production capacity, digital certification, and preparedness for emerging variants. Europe has emphasized coordinated regulatory assessment, joint scientific guidance, vaccine safety transparency, and seasonal immunization alignment across national health systems, with continued attention to older adults, immunocompromised populations, and healthcare workers. North America has transitioned toward risk-based booster guidance, pharmacy-led access, advanced safety monitoring, updated vaccine formulations, and strong genomic surveillance supported by mature regulatory systems and integrated healthcare data. Latin America continues to focus on improving booster coverage among vulnerable groups, strengthening primary care integration, and reducing access disparities across urban, rural, remote, and indigenous communities. Africa's COVID-19 vaccine environment is shaped by access equity, last-mile delivery, cold-chain limitations, vaccine confidence, and the expansion of regional manufacturing ambitions under broader health security agendas. The Middle East has advanced digital vaccination records, border health systems, and healthcare modernization initiatives while prioritizing protection for high-risk residents, expatriate populations, and people with chronic disease. Across all regions, policy attention is shifting toward sustainable immunization infrastructure, variant monitoring, transparent safety communication, and preparedness for future coronavirus threats.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC

NATO members approach COVID-19 vaccination through the lens of health security, military readiness, workforce continuity, resilience of critical infrastructure, and protection of deployed personnel and essential services. G7 countries remain influential in advanced vaccine research, regulatory standards, pandemic financing, genomic surveillance, and support for global health initiatives aimed at equitable access and outbreak preparedness. BRICS economies represent a major force in vaccine manufacturing, technology transfer, clinical research, and South-South health cooperation, with members contributing to domestic immunization programs and broader supply resilience across emerging economies. The European Union has played a major role in harmonized regulatory review, pharmacovigilance, procurement coordination, safety communication, and public health guidance, while member states retain responsibility for national vaccination schedules and delivery models. ASEAN countries continue to prioritize regional health cooperation, cross-border surveillance, and practical vaccination delivery across highly varied healthcare systems, with COVID-19 vaccine programs increasingly embedded into routine adult immunization and public health preparedness. The GCC has used centralized healthcare governance, digital health platforms, and strong logistics capabilities to support vaccine access, certification, booster delivery, and protection of highly mobile populations. Collectively, these groups shape vaccine diplomacy, regulatory convergence, manufacturing localization, procurement strategy, public trust initiatives, and preparedness planning across the global COVID-19 vaccine ecosystem.

Key Country Insights Across Major COVID-19 Vaccine Markets

China has focused on large-scale domestic vaccination, elderly coverage, and ongoing evaluation of variant protection, supported by domestic vaccine development and extensive public health mobilization. The United States has shifted COVID-19 vaccination into routine healthcare channels, with updated vaccine recommendations focused on preventing severe disease among older adults, immunocompromised individuals, and other high-risk groups. Japan prioritizes safety communication, elderly protection, and orderly booster implementation through municipal systems, while India combines extensive vaccine manufacturing capacity with large public health delivery networks and digital certification infrastructure. Germany, the United Kingdom, France, Italy, and Spain continue to align vaccination policy with scientific advisory committees, European regulatory guidance where applicable, older adult protection, seasonal respiratory campaigns, and healthcare system capacity planning. Australia applies risk-based recommendations supported by primary care and pharmacy delivery, and South Korea combines digital health systems, strong public health coordination, and variant monitoring to guide vaccination strategy. Canada emphasizes public health guidance, provincial and territorial delivery systems, indigenous and remote community access, and continued safety surveillance. Russia maintains domestic vaccine development capabilities and public sector immunization structures. Brazil relies on its established national immunization infrastructure to support broad vaccine delivery and booster campaigns, while Mexico focuses on access through public immunization channels and protection of vulnerable populations. Across these countries, the common priorities are updated vaccine access, public trust, adverse event monitoring, equitable delivery, and integration of COVID-19 vaccination into long-term respiratory disease management.

Actionable Recommendations for COVID-19 Vaccine Industry Leaders

Industry leaders should prioritize agile vaccine platform development, variant-responsive formulation strategies, and evidence generation focused on protection against severe disease, hospitalization, and medically significant outcomes. Organizations should invest in real-world evidence, immunobridging studies, pharmacovigilance analytics, and transparent safety communication to support regulatory confidence and public trust. Manufacturing strategies should emphasize flexible capacity, diversified suppliers, quality-by-design systems, validated release processes, and resilient cold-chain logistics to reduce disruption risk. Commercial and public health teams should align access models with routine adult immunization pathways, pharmacies, primary care networks, occupational health programs, long-term care facilities, and community outreach. Leaders should also strengthen collaboration with governments, academic institutions, public health agencies, and multilateral organizations to improve surveillance, data sharing, and equitable distribution. Digital tools, including AI-enabled demand planning and safety monitoring, should be deployed with strong validation, privacy safeguards, cybersecurity controls, and governance. To improve uptake, communication strategies must address vaccine fatigue, misinformation, risk perception, and culturally specific concerns through trusted healthcare professionals and community-based messengers.

Research Methodology for COVID-19 Vaccine Intelligence

This executive summary is developed using a structured secondary research approach grounded in verified public health, regulatory, scientific, and policy sources. The methodology includes review of guidance from national and international health authorities, vaccine advisory committee recommendations, regulatory updates, peer-reviewed scientific literature, immunization program documents, pharmacovigilance publications, and publicly available epidemiological surveillance materials. Evidence is assessed for source credibility, recency, methodological transparency, and relevance to COVID-19 vaccine development, authorization, deployment, safety monitoring, access, and public health impact. Regional, group, and country insights are synthesized through comparative analysis of vaccination policy, healthcare infrastructure, manufacturing capabilities, access conditions, surveillance systems, and preparedness priorities. The research avoids unsupported projections and does not include market sizing, market share, or forecasting. Instead, it focuses on data-backed qualitative intelligence, observable policy shifts, technology adoption, regulatory developments, and operational factors shaping the COVID-19 vaccine environment.

Conclusion on the Evolving Role of COVID-19 Vaccines

COVID-19 vaccines have moved from emergency pandemic response tools to an enduring component of respiratory disease prevention, health security, and immunization policy. The sector is now defined by variant adaptation, targeted booster strategies, real-world effectiveness evidence, safety transparency, manufacturing resilience, and equitable access. Regional and national differences in healthcare infrastructure, public trust, regulatory coordination, and delivery capacity continue to shape vaccine uptake and program design. Artificial intelligence, genomic surveillance, and advanced analytics are strengthening the ability to detect viral changes, optimize vaccine development, manage supply chains, and monitor safety signals. For industry leaders, success will depend on scientific agility, public health alignment, trusted communication, resilient operations, and sustained collaboration across the vaccine ecosystem. As SARS-CoV-2 continues to circulate, COVID-19 vaccination will remain a core element of preparedness for future variants, long-term respiratory disease management, and broader pandemic resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. COVID-19 Vaccines Market, by Vaccine Technology

  • 7.1. Introduction
  • 7.2. Inactivated
  • 7.3. mRNA
  • 7.4. Protein Subunit
    • 7.4.1. Adjuvanted
    • 7.4.2. Non Adjuvanted

8. COVID-19 Vaccines Market, by Dosage Regimen

  • 8.1. Introduction
  • 8.2. Booster Dose
  • 8.3. Single Dose
  • 8.4. Two Dose

9. COVID-19 Vaccines Market, by Packaging Type

  • 9.1. Introduction
  • 9.2. Prefilled Syringe
  • 9.3. Vial

10. COVID-19 Vaccines Market, by Application Route

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intranasal

11. COVID-19 Vaccines Market, by End User

  • 11.1. Introduction
  • 11.2. Adolescent
  • 11.3. Adult
  • 11.4. Child

12. COVID-19 Vaccines Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. COVID-19 Vaccines Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. COVID-19 Vaccines Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AIVITA Biomedical, Inc.
  • 16.2. Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
  • 16.3. Arcturus Therapeutics Holdings Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Baseimmune Ltd.
  • 16.6. Bharat Biotech International Limited
  • 16.7. Biological E. Limited
  • 16.8. CanSino Biologics Inc.
  • 16.9. Centivax, Inc.
  • 16.10. Codagenix Inc.
  • 16.11. CureVac SE
  • 16.12. Emergex Vaccines Holding Ltd.
  • 16.13. eTheRNA immunotherapies NV
  • 16.14. Gennova Biopharmaceuticals Ltd.
  • 16.15. GlaxoSmithKline plc
  • 16.16. HDT Bio Corp.
  • 16.17. Johnson & Johnson
  • 16.18. Medicago Inc.
  • 16.19. Meissa Vaccines, Inc.
  • 16.20. Merck & Co., Inc.
  • 16.21. Moderna, Inc.
  • 16.22. Novavax, Inc.
  • 16.23. Osivax SAS
  • 16.24. Panacea Biotec Ltd.
  • 16.25. Pfizer Inc.
  • 16.26. Providence Therapeutics Holdings Inc.
  • 16.27. Sanofi
  • 16.28. Serum Institute of India Pvt. Ltd.
  • 16.29. Sinopharm Group Co., Ltd.
  • 16.30. Sinovac Biotech Ltd.
  • 16.31. Vaccitech PLC
  • 16.32. Valneva SE
  • 16.33. VBI Vaccines Inc.
  • 16.34. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COVID-19 VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADJUVANTED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADJUVANTED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADJUVANTED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON ADJUVANTED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON ADJUVANTED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON ADJUVANTED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BOOSTER DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOOSTER DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BOOSTER DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TWO DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TWO DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TWO DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADOLESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADOLESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADOLESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. NATO COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. NATO COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. NATO COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 100. NATO COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 101. NATO COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NATO COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 103. NATO COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. G7 COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. G7 COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 107. G7 COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. G7 COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. G7 COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 110. G7 COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GCC COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 135. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 136. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. JAPAN COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. JAPAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. JAPAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 157. JAPAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 158. JAPAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. JAPAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 160. JAPAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. INDIA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. INDIA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. INDIA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 164. INDIA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 165. INDIA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. INDIA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. INDIA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GERMANY COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. GERMANY COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. GERMANY COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 171. GERMANY COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 172. GERMANY COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GERMANY COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AUSTRALIA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 185. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 186. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 199. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 200. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 202. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. RUSSIA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. RUSSIA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 220. RUSSIA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 246. GLOBAL COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025